Karin Conde is the Chief Scientific Officer at Valo Health, where she leads the scientific strategy and the development of innovative platforms to accelerate the creation of new medicines. With more than two decades of experience in the pharmaceutical industry, she has held leadership roles at Novo Nordisk, Hoffmann-La Roche, and Johnson & Johnson, driving discovery and early development programs in areas such as diabetes, obesity, cardiovascular, renal, and liver diseases, as well as rare disorders.
Throughout her career, Karin has been a key figure in external innovation, building strategic partnerships among large pharmaceutical companies, biotech firms, venture capital, and academia. She has led multidisciplinary global teams and managed multiple therapeutic modalities, ranging from small molecules to advanced biologics.
Recognized as a Fierce Leader and one of the leading Women in Pharma, she is also an active advocate for diversity, inclusion, and psychological safety in science, as well as a mentor to early-career researchers. In addition, she serves on several academic boards, where she contributes to strengthening educational programs and fostering innovation in biomedical research.